Fruzaqla
Payments companies reported to CMS as associated with Fruzaqla. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fruzaqla, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fruzaqla
These are the largest totals companies reported as associated with Fruzaqla. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Maen Abdelrahim | Houston, TX | Medical Oncology | $249,046.54 |
| Farshid Dayyani | Orange, CA | Medical Oncology | $224,207.86 |
| Sakti Chakrabarti | Cleveland, OH | Hematology & Oncology | $193,627.92 |
| Raji Shameem | Orlando, FL | Medical Oncology | $166,980.81 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $120,404.18 |
| Mohammed Al Hallak | Detroit, MI | Hematology & Oncology | $108,364.76 |
| Abhirami Vivekanandarajah | Staten Island, NY | Hematology & Oncology | $98,376.97 |
| Abigail Smith | Philadelphia, PA | Adult Health (Nurse Practitioner) | $67,389.21 |
| Grant Williams | Birmingham, AL | Hematology & Oncology | $63,650.59 |
| Howard Hochster | New Haven, CT | Medical Oncology | $51,600.70 |
Prescribed Fruzaqla?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.